long intergenic non-protein coding RNA 2343Genealiases: []
Q-omics provides the consensus-scored LINC02343 profile across patient tissues and cancer cell-line models. LINC02343 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC02343 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LINC02343 RNA expression shows 7,704 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, KIRC, and BRCA as cancer lineages where LINC02343 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02343 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02343 survival associations across molecular data types. LINC02343 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02343 RNA expression–survival associations across cancer types. High LINC02343 expression shows unfavorable associations in MESO, ESCA, THCA and LAML, but favorable associations in LGG and PRAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .016). Together, the overview and detailed table identify MESO as the clearest survival context for LINC02343 RNA expression.
This table summarizes LINC02343 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02343. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02343 shows lower tumor expression in KIRC, KIRP, KICH and HNSC and higher tumor expression in THCA and LUAD. The KIRC box plot shows higher LINC02343 RNA expression in normal versus tumor tissue (log2 FC = −2.443, t-test p < 0.001).
This table shows molecular features associated with LINC02343 in patient tissues and cancer cell lines. In patient samples, LINC02343 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
